Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
Andrew Spakowitz is a Professor of Chemical Engineering, Materials Science and Engineering, and by courtesy, Applied Physics and Chemistry at Stanford University. He currently serves as the Senior Associate Dean for Research and Faculty Affairs and holds the Tang Family Foundation Chair of the Department of Chemical Engineering. His academic career at Stanford spans from Assistant Professor (2006-2014) to Associate Professor (2014-2020) and now Professor since 2020. Dr. Spakowitz earned his PhD in 2004, MS in 2001 from the California Institute of Technology, and his BS in Chemical Engineering from the University of Wisconsin, Madison in 1999. He completed postdoctoral training in Molecular and Cell Biology and Biophysics at UC Berkeley from 2004-2006. His research focuses on theoretical and computational approaches to understanding biological processes and complex materials. The Spakowitz lab addresses fundamental chemical and physical phenomena through four main research themes: chromosomal organization and dynamics, protein self-assembly, polymer membranes, and charge transport in conducting polymers. His group employs diverse theoretical and computational methods including analytical theory of semiflexible polymers, polymer field theory, continuum elastic mechanics, Brownian dynamics simulation, equilibrium and dynamic Monte Carlo simulations, and reaction-diffusion modeling. Analysis of his recent publications reveals a strong emphasis on epigenetics and chromatin dynamics, with significant work on DNA methylation patterns, nucleosome clustering, and chromosome organization. His research also extends to polymer physics applications in biological systems, particularly in respiratory diseases, water purification membranes, and bacterial phage interactions with human mucus. Tang Family Foundation Chair of the Department of Chemical Engineering Professor Spakowitz mentors several graduate students and postdoctoral scholars in the Chemical Engineering and Materials Science departments. His lab members work on diverse projects spanning from chromatin dynamics to polymer membranes for water purification. He teaches multiple courses including CHEMENG 120B (Energy and Mass Transport), CHEMENG 340 (Molecular Thermodynamics), CHEMENG 466 (Polymer Physics), and CHEMENG 467 (Physics of Biomacromolecules). The Spakowitz lab operates from Clark S295 at Stanford University, conducting theoretical and computational research that bridges chemistry, physics, biology, and engineering disciplines to address complex problems across multiple length and time scales.
California Institute of Technology (Caltech)United States
Shasha Chong is an Assistant Professor of Chemistry at the California Institute of Technology and a Ronald and JoAnne Willens Scholar. She earned her B.S. from the University of Science & Technology of China (2008) and Ph.D. from Harvard University (2014). Her research bridges chemistry, physics, and biology to investigate the molecular mechanisms of cellular processes, focusing on intrinsically disordered regions (IDRs) in transcription proteins. Research Focus: IDRs in transcriptional regulation, cancer biology, liquid-liquid phase separation, and single-molecule imaging techniques. Grants & Awards: CCE Innovation Award (2024), ALSF Innovation Grant, Mallinckrodt Research Grant, Margaret E. Early Medical Research Trust Grant. Collaborations: Caltech-City of Hope Biomedical Research Initiative Grant (2025). Teaching: Co-instructor for courses like Biochemistry Laboratory (Ch 11) and Advanced Topics in Biochemistry (BMB/Bi/Ch 174). Labs & Teams: Leads the Chong Laboratory at Caltech, focusing on interdisciplinary approaches combining single-molecule imaging, genome editing, and bioinformatics.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
John Paisley is an Associate Professor of Electrical Engineering at Columbia University's Fu Foundation School of Engineering and Applied Science, and a member of Columbia's Data Science Institute (DSI). He holds a B.S., M.S., and Ph.D. in Electrical and Computer Engineering from Duke University (2004-2010), followed by postdoctoral research in Computer Science at Princeton University and UC Berkeley. His research focuses on Bayesian models, posterior inference techniques for Big Data, and applications in data analysis, recommendation systems, information retrieval, and compressed sensing. He has pioneered methods like Bayesian Gaussian Process ODEs and Double Normalizing Flows, with recent work emphasizing uncertainty quantification in environmental modeling and neuroimaging analysis. His collaborative workflows (e.g., bneR ) address air pollution exposure and PM2.5 concentration uncertainties, combining Bayesian nonparametric ensembles with geospatial data. He has also developed frameworks for neural network interpretability, image denoising, and compressed sensing MRI. Paisley's work bridges statistical theory and applied machine learning, with applications in healthcare, environmental science, and geophysics. His academic contributions include over 50 publications since 2016, spanning topics like deep metric learning, adversarial learning, and variational inference optimization. He maintains an active research group and serves on editorial boards for machine learning and signal processing journals.
Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.
Professor Mark Coles serves as Professor of Immunology and Lead for Industrial Strategy and Entrepreneurship at the Kennedy Institute of Rheumatology, University of Oxford, holding concurrent roles as Kennedy Trust Senior Research Fellow, Official Fellow at Reuben College, and Affiliate Faculty at the Wolfson Centre of Mathematical Biology. His interdisciplinary work bridges immunology, computational modeling, and translational research to accelerate therapies for immune-mediated inflammatory diseases. His academic journey began with a BSc in Microbiology from Cornell University (1992), followed by a PhD in Molecular and Cell Biology at UC Berkeley under David Raulet, and postdoctoral training with Dimitris Kioussis at the National Institute of Medical Research. At the University of York (2006-2017), he pioneered stromal immunology research and co-founded the York Computational Immunology Laboratory. Coles' research centers on stromal and systems immunology, with core expertise in stromal cell biology, inflammatory disease mechanisms, and mathematical modeling of immune responses. He champions 3Rs-based approaches (Replacement, Reduction, Refinement) to reduce animal testing through in silico models, integrating spatial single-cell biology with multi-scale computational frameworks to dissect immune function in human tissues. His 2025 publications reveal a cohesive research trajectory applying interdisciplinary methods across diverse disease contexts—from cardiac fibrosis and vaccine responses to arthritis pathogenesis and CAR-T cell therapy—unified by focus on stromal-immune crosstalk and quantitative modeling to identify therapeutic targets. Key honors include: Fellow of the Royal Society of Biology Kennedy Trust Senior Research Fellow As former Director of Graduate Studies (2017-2024) at the Kennedy Institute, Coles mentored numerous graduate students while co-leading major initiatives including the Arthritis Therapy Acceleration Program and Human Cell Atlas medicalization. His entrepreneurial impact spans three co-founded ventures: Simomics Ltd (in silico disease modeling), Lightox Ltd (phototherapy for oral cancer), and Mestag Therapeutics (fibroblast-targeted therapies for cancer/inflammation). He directs the Laboratory of Stromal and Systems Immunology and Oxford Mathematical Immunology Group, fostering collaborations with Christopher Buckley, Calliope Dendrou, and Eamonn Gaffney to develop Quantitative Systems Pharmacology models that translate mechanistic insights into patient therapies.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Itsik Pe'er is a Full Professor and Vice-Chair in the Department of Computer Science at Columbia University's Fu Foundation School of Engineering & Applied Science, and holds a joint appointment as Professor of Systems Biology at the Vagelos College of Physicians and Surgeons. His research focuses on computational methods in human genetics, including genetic variation analysis, disease association studies, and algorithm development for genomic data. He leads the Itsik Pe'er Lab of Computational Genomics, which develops tools like Xplorigin, Germline, and SEACells to address challenges in genomics and medical research. His work spans machine learning applications in healthcare, microbiome analysis, and cancer genomics. Notable contributions include studies on hypertensive disorders in pregnancy, bias correction in predictive models, and the development of non-Euclidean learning libraries like Manify. Pe'er has advised students including Vladimir Vacic, Anat Kreimer, and Arthi Ramachandran, and collaborates on grants addressing genetic epidemiology and computational biology. His lab's location is in the Computer Science Building at Columbia's Morningside Campus.
University of California, Los AngelesUnited States
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Dr. Yogambha Ramaswamy is a Senior Lecturer in the School of Biomedical Engineering at The University of Sydney and a member of the Sydney Nano Institute. She holds a Master’s in Biotechnology from the University of Queensland and a PhD in Biomedical Engineering from the University of Sydney (2009). Her postdoctoral career began as a Vice-Chancellor’s Postdoctoral Research Fellow at the University of New South Wales, followed by a Peter Doherty Early Career Fellowship in 2013 before joining the University of Sydney in 2015. Dr. Ramaswamy’s research focuses on biomaterials, tissue engineering, and mechanobiology, with a particular emphasis on developing calcium silicate-based ceramics and biopolymers for orthopedic and regenerative applications. Her recent work explores the role of physical cues in modulating stem and cancer cell behavior. She teaches courses such as AMME1961 (Introduction to Biomedical Engineering B) and AMME5962 (Introduction to Mechanobiology). Her research has been supported by grants including the NHMRC Early Career Fellowship and collaborations with institutions like the CSIR-Indian Institute of Chemical Technology and the University of Otago. Her publications span biomaterials, nanotechnology, and mechanobiology, with recent work addressing atherosclerosis, hydrogel design, and nanomedicine. She currently supervises PhD students Frank (biomaterials) and Alexander (atherosclerosis research).
Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.
Emma Pierson is an Assistant Professor of Computer Science at the University of California, Berkeley, affiliated with the Berkeley Artificial Intelligence Research Lab (BAIR) , Computational Precision Health , and the Center for Human-Compatible AI . She focuses on developing data science and machine learning methods to address issues in healthcare equity and social inequality . Her work includes studies on race adjustments in clinical algorithms, migration patterns, and leveraging LLMs for health equity. Education: Ph.D. in Computer Science from Stanford University (2020), Master’s in Statistics from the University of Oxford. Prior roles include Assistant Professor at Cornell Tech, Senior Researcher at Microsoft Research, and data scientist at 23andMe and Coursera. Research Interests: Her research spans fair clinical prediction , sparse autoencoders , health disparities , and algorithmic fairness . Notable projects include the MIGRATE dataset for granular migration analysis and studies on policing disparities. Awards: NSF CAREER Award, Rhodes Scholarship, Hertz Fellowship, MIT Technology Review 35 Innovators Under 35, and Samsung AI Researcher of the Year. She writes a statistics blog ( Obsession with Regression ) and contributes to media outlets like The New York Times and FiveThirtyEight . Labs/Teams: Leads the MIGRATE project, a collaboration to analyze fine-grained migration data. Engages in interdisciplinary work across AI, healthcare, and social science.
